Allegro shares promising preclinical results for osteoarthritis treatment

Ella Day | March 26, 2025 | News story | Clinical Trial Services, Research and Development |  Allegro, Orthopaedics, biomedical, clinical studies, osteoarthritis 

Allegro has announced that hydrocelin, its injectable microparticle hydrogel, showed no signs of toxicity in two preclinical studies.

Allegro is a biomedical company that develops nanotechnology-based treatments for degenerative joint disease.

The preclinical studies were conducted in rats for periods of four and 13 weeks, respectively. Hydrocelin was injected into four separate locations, and a negative control group received saline solution. There was no evidence of systemic toxicity in either study.

Advertisement

Lucas Decuypere, Allegro’s chief executive officer, stated: “It is gratifying to be able to announce another set of positive results as we near a first-in-human testing for hydrocelin.

“Allegro is working tirelessly to give mobility back to the millions of people around the world whose life is severely impacted by osteoarthritis, a disease for which there is not currently a disease-modifying treatment. We believe the unique properties of hydrocelin, if confirmed in clinical studies, could be a huge step in achieving that goal.”

The positive safety results confirmed what the company had established in previously published preclinical studies. Allegro is planning a multi-centre clinical study later in 2025, preparing hydrocelin for osteoarthritis patients. Also, it intends on a commercial launch in 2027.

Ella Day
26/3/25

Related Content

Allegro confirms successful safety testing of osteoarthritis treatment

Allegro’s hydrocelin treatment for osteoarthritis has demonstrated a satisfactory safety profile, giving it potential to …

Santhera Pharmaceuticals announces LIONHEART study results for corticosteroid vamorolone

Santhera Pharma has announced the results of its LIONHEART study, which evaluated vamorolone – a …

Rheumatoid arthritis

Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment

Biotechnology company Levicept has announced positive results from its phase 2 trial into LEVI-04, for …

The Gateway to Local Adoption Series

Latest content